Effect of Intracuff Alkalinized Lignocaine on the Incidence of Post Operative Sore Throat and Cough by Nasreen Kaja,
 1 
A Dissertation on 
 
EFFECT OF INTRACUFF ALKALINIZED LIGNOCAINE ON THE 
INCIDENCE OF POST OPERATIVE SORE THROAT AND COUGH  
submitted to 
 
THE TAMILNADU DR. M.G.R. MEDICAL UNIVERSITY 
 
                                 In partial fulfillment of the  requirements
   for the award of the degree 
M.D.  (BRANCH-X)  
ANAESTHESIOLOGY 
 
 
 
 
 
GOVERNMENT STANLEY MEDICAL COLLEGE & HOSPITAL 
THE TAMILNADU DR. M.G.R. MEDICAL UNIVERSITY 
CHENNAI, TAMILNADU  
MAY 2019 
 2 
 
DECLARATION BY THE CANDIDATE 
 
I, DR. NASREEN KAJA , solemnly declare that the dissertation, titled "EFFECT 
OF INTRACUFF ALKALINIZED LIGNOCAINE ON THE INCIDENCE OF 
POST OPERATIVE SORE THROAT AND COUGH “  is a bonafide work done 
by me during the period of APRIL 2018 to SEPTEMBER 2018 at Government 
Stanley Medical  College  and  Hospital,  Chennai  under  the  expert  supervision  of                     
Dr. DHANASEKARAN M.D., D.A.,  Professor, Department Of Anaesthesiology, 
Government Stanley medical college,Chennai. 
 
This thesis is submitted to The Tamil Nadu Dr. M.G.R. Medical University in 
partial fulfillment of the rules and regulations for the M.D. degree examinations in 
Anaesthesiology to be held in may 2019 
 
 
Date : Dr. NASREEN KAJA 
 
 
Chennai-01
 3 
CERTIFICATE BY HEAD OF THE DEPARTMENT 
 
 
 
This is to certify that the dissertation titled "EFFECT OF INTRACUFF 
ALKALINIZED LIGNOCAINE ON THE INCIDENCE OF POST 
OPERATIVE SORE THROAT AND COUGH “ is a genuine work done by 
DR. NASREEN KAJA  for the partial fulfilment of the 
requirementsforM.D.(Anaesthesiology)ExaminationofTheTamilnaduDr. 
M.G.R. Medical University to be held in May 2019, under my supervision and 
guidance. 
 
 
 
 
 
Dr. NAHEED AZHAR M.D., D.A. DNB, 
Professor and HOD 
Department of Anaesthesiology, 
Stanley Medical College, 
Chennai - 01 
 4 
 
CERTIFICATE BY THE GUIDE 
 
 
This is to certify that the dissertation titled "EFFECT OF INTRACUFF 
ALKALINIZED LIGNOCAINE ON THE INCIDENCE OF POST 
OPERATIVE SORE THROAT AND COUGH “ is a genuine work done by 
DR. NASREEN KAJA  for the partial fulfilment of the 
requirementsforM.D.(Anaesthesiology)ExaminationofTheTamilnaduDr. M.G.R. 
Medical University to be held in May 2019 , under my supervision and 
guidance. 
 
 
 
 
 
Dr. DHANASEKARAN , M.D., D.A., 
Professor and Guide 
Department ofAnaesthesiology, 
Stanley Medical College and Hospital, 
Chennai - 600 001. 
 5 
 
ENDORSEMENT BY HEAD OF THE INSTITUTION 
 
 
This is to certify that the dissertation "EFFECT OF INTRACUFF 
ALKALINIZED LIGNOCAINE ON THE INCIDENCE OF POST 
OPERATIVE SORE THROAT AND COUGH  "presented herein by    
DR. NASREEN KAJA  is an original work done in the Department of 
Anaesthesiology, Government Stanley Medical College and Hospital, Chennai 
in partial fulfilment of regulations of The Tamilnadu Dr. M.G.R Medical 
University for the award of degree of M.D. (Anaesthesiology) branch X, under 
my supervision during the academic period2016-2019. 
 
 
 
 
Dr. S. PONNAMBALA NAMASIVAYAM M.D., D.A.,D.N.B., 
Dean 
Stanley Medical College, 
Chennai -600001 
 6 
 
ACKNOWLEDGEMENTS 
 
 
I wish to express my sincere thanks to Prof. Dr.S. PONNAMBALA 
NAMASIVAYAM M.D.,D.A.,D.N.B., Dean, Government Stanley Medical 
College and Hospital for having permitted me to utilize the facilities of the 
hospital for the conduct of thestudy. 
 
 
My heartfelt gratitude to Prof. Dr DHANSEKARAN, M.D., D.A., Professor, 
Department of Anaesthesiology, Government Stanley Medical College and 
Hospital for her motivation, valuable suggestions, expert supervision, guidance 
and for making all necessary arrangements for conducting this study. 
 
I   thank   Prof.   Dr.  NAHEED AZHAR M.D.,D.A.,D.N.B., Professor and Head, 
Department of Anaesthesiology, Government Stanley Medical College and Hospital for 
his constant encouragement and support. 
 
 
 
 7 
I thank Prof. Dr. KUMUDHA LINGARAJ, M.D., D.A., for her invaluable 
encouragement throughout the course of the study. 
I thank Prof. Dr. NALINI, M.D., D.A., for her constant motivation and 
valuable suggestions in carrying out this study. 
I thank Prof. Dr. SEVAGAMOORTHY, M.D., D.A., for his constant 
motivation and valuable suggestions for my study. 
I express my heartfelt gratitude to my Assistant Professor  
Dr.N.V. MADHAVAKRISHNA  M.D., who had evinced constant and keen 
interest in the progress of my study right from the inception till the very end and 
were instrumental in the successful completion of the study. 
I wish to thank all my Assistant Professors especially for their aid and 
encouragement during the study.  
I thank Dr. ARUN ,for helping me in statistical analysis. My sincere thanks to 
all those Post Graduates who helped me during this study period.  
I thank the staff nurses and theatre personnel, Government Stanley Medical 
Hospital for their cooperation and assistance. I owe my gratitude to all the 
patients included in the study and their relatives, for their whole hearted co-
operation and consent. 
 8 
CONTENTS 
 
 
 
 
S.NO 
 
 
CHAPTER 
 
 
PAGE NO. 
1 INTRODUCTION 15 
2 AIM OF THE STUDY 17 
3 HISTORY 18 
4 ENDOTRACHEAL INTUBATION 20 
5 CUFF OF THE ENDOTRACHEAL TUBE 23 
         6 POST OPERATIVE SORE THROAT 31 
7 LOCAL ANAESTHETICS 41 
8 LIGNOCAINE 45 
9 INTRACUFF ALKALINIZED LIGNOCAINE 50 
10 REVIEW OF LITERATURE  54 
11 MATERIALS AND METHODS 66 
12 OBSERVATION AND RESULTS 73 
13 DISCUSSION 89 
14 CONCLUSION 95 
15 BIBLIOGRAPHY 96 
 9 
16 ANNEXURE 
ETHICAL COMMITTEE APPROVAL LETTER 
PATIENT INFORMATION SHEET 
INFORMED CONSENTFORM 
PROFORMA 
MASTERCHART 
PLAGIARISM CERTIFICATE 
 
 10 
TABLES 
 
 
S.NO CONTENT PAGE NO. 
1 COMPLICATIONS AT EXTUBATION  21 
2 DEVICES TO CONTROL ET TUBE CUFF 
PRESSURE 
35 
3 PHARMACOLGY OF LIGNOCAINE  46 
4 LIGNOCAINE TOXICITY 49 
5 CLINICAL USAGE OF LIGNOCAINE  50 
6 POSTOPERATIVE SORETHROAT GRADING  72 
7 GENDER  DISTRIBUTION AMONG THE 
SAMPLE  
75 
8 DISTRIBUTION OF SAMPLE IN TERMS OF 
ASA PHYSICAL STATUS 
77 
9 CUFF PRESSURE AT THE END OF THE 
SURGERY 
 
79 
10 SORE THROAT IMMEDIATELY AFTER 
EXTUBATION  
80 
11 SORE THROAT 1 HOUR AFTER 
EXTUBATION  
82 
12 SORE THROAT 6 HOURS AFTER 
EXTUBATION  
83 
 11 
13 OTHER FEATURES ASSOCIATED WITH 
EXTUBATION  
85 
14 DIFFERENCE IN POSTOPERATIVE 
SEVERITY BETWEEN MALE AND FEMALE 
IN INTRACUFF AIR GROUP AT 0 MINS 
88 
15 DIFFERENCE IN POSTOPERATIVE 
SEVERITY BETWEEN MALE AND FEMALE 
IN INTRACUFF ALKALINIZED 
LIGNOCAINE GROUP AT 0 MINS 
88 
 
 
 
 
 
 
 
 
 12 
FIGURES 
 
S.NO FIGURE PAGE NO. 
1 TRACHEAL MUCOSAL INJURY SECONDARY 
TO ET TUBE CUFF OVERINFLATION  
23 
2 TYPES OF CUFFS 25 
3 COMPARISON OF LOW VOLUME HIGH 
PRESSURE AND HIGH VOLUME LOW 
PRESSURE CUFF 
26 
4 FOAM CUFF  27 
5 LANZ CUFF 28 
6 ET TUBE CUFF PRESSURE MONITORING  28 
7 EFFECT OF ET TUBE CUFF PRESSURE ON 
TRACHEAL MUCOSAL PERFUSION  
29 
8 CONTACT ULCER GRANULOMA  38 
9 HAEMATOMA OF VOCAL CORD  39 
10 MECHANISM OF ACTION OF LOCAL 
ANAESTHETICS  
41 
11 VARIATION OF PLASMA CONCENTRATION 
OF LIGNOCAINE WITH TIME 
47 
12 METABOLISM OF LIGNOCAINE  48 
 13 
13 AGE  DISTRIBUTION IN AIR GROUP  74 
14 AGE DISTRIBUTION IN LIGNOCAINE GROUP  74 
15 GENDER DISTRIBUTION OF THE SAMPLE  75 
16 DISTRIBUTION OF SAMPLE WITH RESPECT 
TO SURGICAL PROCEDURE WHILE USING 
AIR AS CUFF INFLATION MEDIUM  
76 
17 DISTRIBUTION  OF SAMPLE WITH RESPECT 
TO SURGICAL PROCEDURE WHILE USING 
ALKALINIZED LIGNOCAINE AS CUFF 
INFLATION MEDIUM  
76 
18 ASA PHYSICAL STATUS 77 
19 CUFF PRESSURE AT THE END OF 
SURGERY  
78 
20 SORE THROAT IMMEDIATELY AFTER 
EXTUBATION  
80 
21 SORE THROAT AT 1 HOUR AFTER 
EXTUBATION  
81 
22 SORE THROAT AT 6 HOURS AFTER 
EXTUBATION  
83 
23 OTHER FEATURES ASSOCIATED WITH 
EXTUBATION  
84 
 14 
24 DIFFERENCE BETWEEN MALE AND 
FEMALE IN INTRACUFF AIR GROUP 
86 
25 DIFFERENCE BETWEEN MALE AND 
FEMALE IN INTRACUFF LIGNOCAINE  
GROUP 
87 
 15 
CHAPTER 1 
INTRODUCTION 
Post operative sore throat is the most common complaint after endotracheal 
intubation and is seen in upto 90% of the patients. It maybe considered along with 
endotracheal tube emergence phenomenon with laryngeal edema and ischemia. 
Chemical and mechanical irritation of the tracheal mucosa influences the incidence 
of cough at emergence from general anesthesia, potentially leading to significant 
postoperative complications.  
Sore throat during emergence in a lighter plane of anaesthesia can result in 
detrimental hemodynamic changes. These changes are particularly undesirable in 
patients undergoing neurosurgical and, ophthalmic or those who have an increased 
risk of adverse cardiovascular event. Both in-vivo and in-vitro studies have been 
conducted on endotracheal tube cuffs filled with lignocaine. Past studies using high 
doses of lignocaine are associated with complications in the event of rupture of 
cuff. Sodium bicarbonate is hence added to increase the diffusion of lignocaine low 
 16 
doses of through the cuff thereby preventing complications like sore throat, 
restlessness, nausea, vomiting, dysphonia and hoarseness of voice.  
So in this study we compared the effect of intracuff alkalinized lignocaine 
and air in minimizing the incidence of post operative sore throat and cough  after 
endotracheal intubation in general anaesthesia.  
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CHAPTER 2 
AIM OF THE STUDY 
PRIMARY OUTCOME: 
 To compare the incidence of post operative sore throat after general anaesthesia 
while using  air and alkalinized lignocaine as the cuff inflation media of the 
endotracheal tube.   
 
SECONDARY OUTCOME:  
To  study the incidence of cough, vomiting,  hoarseness of voice and aspiration 
after extubation while inflating the cuff of the endotracheal tube with alkalinized 
lignocaine.  
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CHAPTER 3 
HISTORY 
The development of techniques and instruments for intubation ranks among 
the major advances in the history of anaesthesia(1). The first use of elective oral 
intubation was undertaken by Scottish surgeon , William Macewan(2).                                            
In 1926, Arthur Guedel began a series of experiments that lead to the 
introduction of the cuffed tube. He fashioned cuffs from the rubber of dental dams, 
condoms, surgical gloves that were glued onto the outer wall of the tubes(3).He 
recommended that the cuff be positioned just below the vocal cords to seal the 
airway. Waters later recommended that cuffs be constructed of two layers of soft 
rubber cemented together. These detachable cuffs were first manufactured by 
Waters’ children.    
Guedel sought ways to show the safety and utility of the cuffed tube. He first 
filled the mouth of an anaesthetized and intubated patient with water and showed 
that the cuff sealed the airway. He reasoned that if the cuff prevented water from 
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entering the trachea of an intubated patient , it should also prevent an animal from 
drowning even if it were submerged under water(4).  
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CHAPTER 4 
ENDOTRACHEAL INTUBATION 
 Tracheal tubes are designed to provide a secured channel through the upper 
airway. The distal end lies in the mid to lower part of trachea, whereas the 
proximal end lies outside the mouth or nose where it is connected to the 
anaesthesia circuit or other device(5).Tracheal tubes used in adult patients have a 
cuff near the distal end that is inflated to provide a seal against the tracheal wall to 
protect the lungs from pulmonary aspiration and to ensure that the tidal volume 
delivered ventilates the lungs, rather than escapes into the upper airway. Cuffs are 
normally inflated with air and have an inflation tube with a pilot balloon that 
indicates cuff inflation(6). 
 Use of small tracheal tubes reduces the incidence of sore throat and 
hoarseness of voice. Small tracheal tubes may cause less tissue pressure in larynx.    
Cuff inflation achieves a seal between the tracheal tube and the wall of the trachea. 
There should be no air leak at airway pressures required for positive pressure 
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ventilation and the lungs should be protected from aspiration. The tracheal tube 
must be long enough for the cuff to lie 2 cm beyond the vocal cords. 
PHYSIOLOGICAL RESPONSE TO TRACHEAL INTUBATION: (7) 
    Direct laryngoscopy and passage of a tracheal tube are noxious stimuli that 
provoke adverse responses in the cardiovascular, respiratory and other 
physiological systems. The magnitude of the response are greater with increase in 
force and duration of laryngoscope. Hemodynamic changes during tracheal 
intubation are undesirable in patients in cardiac disease and can result in 
myocardial ischaemia but seem to cause little harm to most patients. Many 
techniques have been tried to attenuate the stress response to intubation but none is 
ideal.  
The ASA recommends that the anaesthesiologists have a preformulated strategy 
for extubation and management of post extubation problems.  
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Hypoventilation ( residual effect of anaesthetic drug and neuromuscular blockade) 
Upper airway obstruction 
Laryngospasm and bronchospasm 
Coughing ( wound disruption ) 
Impaired laryngeal competence and pulmonary aspiration  
Hypertension, tachycardia, dysrhythmia, myocardial ischemia 
Table 1. Complications at extubation.  
Extubation may be perfomed at different depths of anaesthesia. Deep 
extubation is performed to avoid adverse reflexes caused by the presence of the 
tracheal tube and its removal at a price of higher risk of hypoventilation and upper 
airway obstruction. Straining which could disrupt the surgical repair, is less likely 
with deep extubation.  
Coughing maybe particularly troublesome during light plane of 
anaesthseiaextubation and cannot be entirely prevented. The frequency of cough 
may be reduced when the volatile used is sevoflurane. Intravenous lignocaine and 
alfentanil can also reduce coughing, as can local anaesthetic in the tracheal tube 
cuff are applied to the airway.  
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CHAPTER 5 
CUFF OF THE ENDOTRACHEAL TUBE 
A cuffed tracheal tube has an inflatable sleeve near the patient end of the 
tube. When this cuff is inflated to the desired volume , it seals the space between 
the tube and tracheal wall. It has an inflation tube connecting pilot balloon to the 
cuff. The pilot balloon has a one way inflation valve. In tubes which do not have 
an inflation valve, cuff inflation is maintained by applying a clamp to the external 
inflation tube or by applying a plug to its free end(8) .  
 
Fig 1:- Mechanism of tracheal mucosa perfusion injury secondary to ETT cuff 
overinflation.  
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Cuffs are classified,  according to the pressure required to inflate the cuff, 
into low volume, high pressure cuffs and high volume, low pressure cuffs.  
Low volume high pressure cuff – the red rubber tubes were made of a relatively 
low compliance thick rubber. These cuffs required a high pressure to distend them 
and were relatively low volume. These cuffs inflate in a circular shape rather than 
conforming to the shape of trachea.   These cuffs have a small diameter at rest and 
a low residual volume. It has a small area of contact with the tracheal wall and 
distends and deforms the trachea in to circular shape. In order to achieve enough 
contact with the tracheal wall and a good seal, relative overinflation was required, 
with the result that the high pressure within the cuff  was transmitted to the tracheal 
wall. This led to the increase in mucosal pressure to critical levels (capillary 
pressure is usually about 35 mmHg) could lead to mucosal ischemia, development 
of tracheal scarring and tracheal stenosis in case of prolonged surgeries. 
Advantages of these cuffs include better protection against aspiration, better 
visibility during intubation than low pressure cuffs, lower incidence of sore throat.  
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High volume low pressure cuffs - They are made from thin inelastic material like 
PVC and h a large resting volume and diameter. As the cuff has a thin wall, it seals 
the trachea without stretching the tracheal wall. As the cuff is inflated, the area of 
contact becomes larger and the cuff adapts itself to the tracheal surface. The 
pressure within the cuff can therefore be kept much lower and can achieve a seal 
with minimal risk of occluding mucosal blood flow. The intracuff  pressure closely 
approximates the pressure on the tracheal wall hence it is possible to measure and 
regulate the pressure exerted on the tracheal mucosa. Therefore there are less 
incidences of cuff related complications following prolonged intubation . 
These cuff also have few disadvantages. It may be more difficult to insert as 
the cuff may obscure the view of the tip and larynx. A number of microfolds 
remain in the cuff even after a good seal and create microchannels running the 
length of the cuff. These channels may cause ventilator associated pneumonia by 
allowing the passage of infective pharyngeal contents beyond the cuff. When 
nitrous oxide is used, it will diffuse into the cuff causing an increased pressure on 
the tracheal mucosa.  
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Fig 2:- Types of cuffs  
 
Fig 3:- Comparison of low volume high pressure and high volume low pressure 
cuffs 
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Foam cuff – It is made up of polyurethane foam and comes with bigger diameter 
and residual volume. The cuff is deflated by applying suction and when the 
negative pressure is released , the cuff expands. When in place, the amount that the 
foam expands determines the pressure exerted laterally on the tracheal wall and it 
is inversely proportional to each other. It provides a good seal at low tracheal wall 
pressure , when used according to appropriate size.  
 
Fig 4:- Foam cuff              
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Lanz cuff -  It comprises of a latex pilot balloon inside a transparent plastic sheath 
and has a pressure regulating valve between the cuff and the balloon. The pilot 
balloon is designed to maintain a intracuff pressure of 20 – 25 torr at the end of 
 expiration. The pressure regulating valve prevents gas leak around the cuff during 
positive pressure ventilation and nitrous oxide related cuff pressure rise. How ever 
it may not give a good seal in patients requiring higher airway pressures.  
 
Fig 5:-Lanz cuff     
 Fig 6:- ETT Cuff pressure monitoring 
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Fig 7:- Effect of ETT cuff pressure on tracheal mucosal perfusion 
An optimal cuff pressure will give a good seal without compromising the 
blood supply of trachea. The recommended pressure on the lateral wall of the 
trachea is between 18- 25mmHg in normotensive adults(13) . 
Leak test is performed to measure the pressure exerted by the cuff of the 
tracheal tube on the tracheal mucosa. The valve on the breathing circuit is closed 
partially. The bag is squeezed with increasing pressure till an audible leak is 
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detected around the tube. The airway pressure at which the audible leak is detected 
is the pressure exerted by the tube on the tracheal mucosa.  
The intracuff pressure and volume of a cuff inflated with air rise, when nitrous 
oxide is administered for a long time. The rate of diffusion depends on the 
permeability of the cuff material, the surface of the cuff exposed to nitrous oxide 
and partial pressure of nitrous oxide. When nitrous oxide administration is 
discontinued, the pressure in the cuff decreases rapidly. It can be measured by 
connecting the inflation tube to the pressure transducer of a monitor or direct 
measurement with a manometer.  
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CHAPTER 6 
POST OPERATIVE SORE THROAT  
Sore throat is a common postoperative complaint, occurring most often 
following endotracheal intubation. Main causative factors include tracheal‐tube 
size and cuff design. Routine tracheal intubation for elective surgical procedures 
can result in pathological changes, trauma and nerve damage which may also 
account for postoperative throat symptoms. However, high intracuff pressure is 
associated with nerve palsies due to neuropraxia and nerve compression. Careful 
insertion techniques for  the tracheal tube  are of  great importance in the 
prevention of airway trauma and postoperative sore throat. 
Other factors that are found to be implicated were surgeries involving the 
head and neck region because of movement of the tube and cuff within the trachea 
and the presence of a nasogastric tube.  
It has been clearly demonstrated that the use of a smaller tracheal tube 
reduces the incidence of sore throat, presumably because of decreased area of 
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contact between the tube and tracheal mucosa and hence decreased pressure at the 
tube–mucosal interface . 
 The tracheal‐tube cuff has been implicated as a cause of serious sequelae 
following long‐term intubation. The red‐rubber tube had a low‐residual‐volume, 
high‐pressure cuff and the exertion of this high pressure on the tracheal mucosa 
was thought to be damaging. A study of blood flow in rabbit tracheal mucosa 
demonstrated that when a high‐pressure, low‐volume cuff was inflated to  
>39cmH2O , the mucosa in contact with the cuff, i.e. that covering the tracheal 
cartilage, became ischaemic(9). This was thought to be due to a more even 
distribution of pressure over the mucosa. These low‐volume high pressures cuffs 
still allowed some perfusion of the mucosa covering the cartilages(10). When a 
thin‐walled, low‐pressure, high‐volume cuff was used, blood flow did not cease 
until intracuff pressures was in the range 80–120 mmHg. Even so, the cautious 
recommendation was made that intracuff pressure should be maintained at 
<26cmH2O.  
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After the introduction of high‐volume, low‐pressure cuffs, Loeser and 
co‐workers(11,12,13,14,15) extensively investigated the effect of using tracheal tubes 
with different cuff designs on the incidence of postoperative sore throat, and 
showed that the high‐volume cuffs were associated with a higher incidence of sore 
throat because of the greater area of cuff–tracheal contact. Although the 
high‐volume cuffs caused a greater area of damage to the tracheal mucosa, the 
damage was more superficial than that caused by the high‐pressure cuffs (16) . It is 
recommended that the ideal cuff should have a diameter slightly less than that of 
the trachea but should be constructed of material that would allow a 10% increase 
in diameter over the range of inflating pressure of 20–30 cmH2O. In this way, 
wrinkling would be avoided, allowance could be made for variation in tracheal size 
when obtaining a seal and intracuff pressures would not compromise the tracheal 
mucosa. Furthermore, the cuff should be narrow in order to minimise the cuff–
tracheal contact area(17). 
High‐volume, low‐pressure cuffs will exert high pressure on the tracheal 
mucosa if overinflated following tracheal intubation, or if no allowance is made for 
N2O diffusion. Both high‐ and low‐volume cuffs undergo similar changes in 
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volume and pressure as a result of N2O diffusion when inflated with air(18).  In an 
animal study, a comparison was made between cuff inflation with either saline or 
air. The pressure in the air‐inflation group was significantly higher than that in the 
saline‐inflation group (19). 
The application of high pressure to the tracheal mucosa may also contribute 
to the occurrence of postoperative sore throat. The Brandt Anaesthesia Tube is 
designed to prevent intracuff pressure from increasing above 25cm H2O, by virtue 
of the cuff communicating through the inflation line with a pilot balloon that is 
more compliant and of higher volume(20). The incidence of postoperative sore 
throat in patients intubated with this  tube (15%) is  significantly lower than that 
after intubation with a standard Mallinckrodt tube (60%) which suggests that 
cuff‐pressure limitation may help reduce the incidence of postoperative sore throat. 
Overinflation may further predispose the patient to postoperative sore throat by 
causing an increase in the cuff–tracheal contact area (21). 
In order to avoid these problems, the cuff seal point should be carefully 
determined after tracheal intubation and that the intermittent measurement and 
adjustment of cuff pressure should be routine clinical practice (22). Alternatively, 
 35 
simple measures such as inflating the cuff with gas drawn from the breathing 
circuit or with saline will avoid the problem of N2O diffusion. 
 
Aneroid manometer 
Brandt anesthesia tube system 
VBM cuff pressure monitor 
Tracoe cuff pressure gauge  
Table 2:- Devices to control endotracheal tube cuff pressure  
The effect of the application of laryngotracheal lignocaine spray on 
postoperative sore throat has also been investigated(23). The incidence of sore throat 
was 29.2% in the study group and 19.6% in the control group. Although this 
difference was not statistically significant, it was concluded that the application of 
lignocaine spray could not be recommended for routine use. It was further 
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suggested that the lignocaine may be irritating or damaging to the tracheal 
mucosa(24). 
There is no study therefore that categorically demonstrates that the use of 
lubricating jelly containing a local anaesthetic is beneficial in the reduction of 
postoperative sore throat after tracheal intubation. The application of lignocaine 
spray before intubation appears to increase the incidence of sore throat, as a result 
of either mucosal irritation or repeated laryngoscopy. 
The role of suxamethonium in the aetiology of postoperative sore throat is 
unclear. It has been suggested that suxamethonium, which is known to cause 
postoperative skeletal muscle pain, could also lead to pain in the striated 
pharyngeal muscles, causing sore throat. In a study of 83 women undergoing 
dilatation and curettage who did not undergo tracheal intubation, the effect of 
administration of suxamethonium was examined(25). Patients who received 
suxamethonium, either as a bolus or by infusion, had a significantly higher 
incidence of sore throat  postoperatively. In summary, the use of smaller tracheal 
tubes with cuffs that have a small area of contact with the tracheal mucosa will 
reduce the incidence of postoperative sore throat. Careful control of intracuff 
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pressure may be beneficial even for short‐term intubation, and consideration 
should be given to using either the anaesthetic gas mixture or saline to inflate the 
cuff. Lubricants containing local anaesthetic agents are not useful and may actually 
increase sore throat incidence  
Pathological changes secondary to intubation include epithelial loss, glottis 
hematoma and edema, submucosal tears and contact ulcer granuloma. 
Laryngeal trauma most commonly occurred posteriorly over the cricoid plate 
and also over the vocal processes of the arytenoids, as a result of forces exerted by 
the rigid tubes.  
Traumatic injury to larynx during intubation can cause post operative sore 
throat because of neuropraxia due to high intracuff pressure and nerve 
demyelination due to gas sterilisation of the tubes. Decreased elasticity of the 
trachea and surrounding tissues in older people may also increase the likelihood of 
damage occurring during laryngoscopy and intubation. 
Contact‐ulcer granuloma is the most common late complication of tracheal 
intubation and should be suspected if the patient complains of prolonged 
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hoarseness. The site of the granuloma was usually at the tip of the vocal processes 
of the arytenoid cartilages, due to, among other things, their incessant 
movement(26).  
 
`  Fig 8:- Contact ulcer granuloma 
Haematoma of the left vocal cord is the most common injury seen on indirect 
laryngoscopy which usually resolves spontaneously(27). Optimisation of intubating 
conditions and careful technique are necessary to minimise airway trauma. 
Overinflation of the tracheal tube cuff has been associated with recurrent laryngeal 
nerve palsy and should be avoided. In summary, extensive damage to the 
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laryngeal and tracheal epithelia occurs as a result of tracheal intubation, even with 
an intubation period as short as 1hour.  
 
Fig 9:- Hematoma of vocal cord 
In most cases, postoperative throat complaints resolve spontaneously 
without specific treatment. In moderate to severe cases it may be beneficial to treat 
pain and dysphagia with a gargle containing a drug such as benzydamine 
hydrochloride, which is approved for the symptomatic treatment of acute sore 
throat pain (28). Benzydamine hydrochloride is a topical nonsteroidal 
anti‐inflammatory agent that also has local anaesthetic activity.  
 40 
Penetrating injuries caused by the laryngoscope blade, the airway or the 
patient's own teeth may require treatment with topical antibiotics (29). 
Symptoms of postoperative throat discomfort such as sore throat, hoarseness 
and dysphagia are common, and are associated with trauma to the larynx and the 
pharynx. Careful airway management technique is therefore essential. Appropriate 
sizes of tracheal tube should be chosen. Lubricants containing local anaesthetics do 
not appear to be beneficial and may actually be harmful, having been implicated as 
a cause of bilateral recurrent laryngeal nerve palsy. Tracheal‐tube cuffs that have 
minimal contact with the tracheal mucosa should be used, and monitoring and 
limitation of tracheal tube cuff pressures should be considered, both to reduce the 
incidence of postoperative sore throat and to minimise the risk of neuropraxia. 
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CHAPTER 7 
LOCAL ANAESTHETICS  
Local anaesthetics block voltage gated sodium channels and interrupt initiation and 
propogation of nerve impulses(30). Currently available local anaesthtics belong to 
two chemical classes namely aminoesters and aminoamides. 
 
Fig 10:- Mechanism of action of local anaesthetics 
Most of their features derive from the requirement for  high solubility and rapid 
diffusion across biological membranes. Reversible protonation of the tertiary 
amine group tends to make local anaesthetic less charged at acidic pH, the neutral 
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base forms are more soluble in lipid environments. The typical local anaesthetic 
molecule contains a tertiary amine linked by an intermediate chain that always 
contains an ester or amide linkage. The aromatic hydrocarbon is hydrophobic in 
character whereas the tertiary amine is relatively hydrophilic. Local anaesthetic 
bases are poorly to sparingly soluble in water but are soluble in relatively 
hydrophobic solutions. Hence to optimize their shelf life most of the drugs are 
formulated as hydrochloride salts. Local anaesthetics with pKa nearest to 
physiological pH have the most rapid onset of action refelecting the presence of 
optimal ratio of ionized to non ionized fraction.   
Aminoesters are metabolized primarily by plasma esterases and 
aminoamides by primarily enzymes. Recent efforts have led to the development of 
several new formulations of topical anaesthesia . 
Hydrophobicity appears to be a primary determinant of the intrinsic 
anaesthetic potency. The onset of the conduction block in isolated nerves is related 
to physicochemical properties of the individual and  the dose or concentration of 
the local anaesthetic used .  
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The duration of anaesthesia is markedly influenced by the peripheral 
vascular effects of the local anaesthetic, at low concentrations these agents tend to 
cause vasoconstriction , at higher concentrations they cause vasodilation. .  
The addition of sodium bicarbonate to local anaesthetic solutions accelerates 
the time for achieving the required concentration( Cm) (30) needed for the 
conduction blockade and increases the amount of the uncharged base form, which 
should permeate the nerve sheath and nerve membrane. Hence sodium bicarbonate 
addition decrease the onset of action of the local anaesthetic solution.  
In addition to blockade of impulses, local anaesthetic inhibits various 
receptors, and enhance the activity of certain intracellular signaling pathways.  
Local anaesthetics in turn can suppress components of inflammatory 
responses by a cascade of systemic reactions.(31, 32)  
Local anaesthetics are used to produce topical anaesthesia by placement on the 
mucous membrane of the nose, mouth, tracheobronchial tree, esophagus or 
genitourinary tract. Cocaine   ( 4 – 10%), tetracaine ( 1-2%) and lignocaine (2-4%) 
are most often used topically. It is estimated that cocaine anaesthesia is used in  
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>50% of rhinolaryngeal procedures performed in the US (33).There is no difference 
between the intranasal anaesthetic or vasoconstrictive effect of cocaine and those 
of lignocaine – oxymetazoline mixture emphasizing its usefulness as a substitute 
for cocaine.  
Nebulized lignocaine is used to produce surface anaesthesia of the upper and 
lower respiratory tract before fibreoptic bronchoscopy and as a treatment for 
patients experiencing intractable coughing (34).The inhalation of local anaesthetics 
by normal subjects does not alter airway resistance and may even cause 
bronchodilation. In contrast local inhalation of local anaesthetics can cause 
bronchoconstriction in some patients with asthma.  
Local anaesthetics are absorbed into the systemic circulation after topical 
application to mucous membranes. Plasma lignocaine concentration 15 minutes 
after layngotrachealsparay are similar to the concentrations present at the same 
time after an IV injection of a similar dose of lignocaine. This reflects the high 
vascularity of the tracheobronchial tree and the injection of the local anaesthetic as 
a spray that spreads the solution over a wide surface area.  
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CHAPTER 8 
LIGNOCAINE 
In 1944, Nils Lofgren and Bengt Lundquist developed lignocaine – an amino 
amide local anaesthetic. It gained immediate popularity because of its potency, 
rapid onset and decreased incidence of allergic reactions and overall effectiveness 
for all types of regional anaesthetic blocks.  Lignocaine contains a tertiary amine 
linked to an amide. The aromatic hydrocarbon is hydrophobic and lipophilic  in 
character whereas the tertiary amine is relatively hydrophilic .The lipid solubility 
of lignocaine is 2.9. 
Lidocaine alters signal conduction in neurons by prolonging the inactivation 
of the fast voltage-gated Na+ channels in the neuronal cell membrane responsible 
for action potentialpropagation(30). 
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Potency  1 
Onset  Rapid  
Duration after infiltration  60-120  min  
Maximum single dose for infiltration  300mg 
Toxic plasma concentration  >5 micrograms/mL 
pKa 7.9 
Protein binding  70% 
Fraction unionized at pH 7.4  25% 
Lipid solubility  2.9 
Volume of distribution  91L 
Clearance  0.95 L/min  
Elimination half time  96 min  
 
Table 3 :- Pharmacology of lignocaine  
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Fig 11:- Variation of plasma concentration of lignocaine with time  
The principal metabolic pathway of lignocaine is oxidative dealkylation in 
the liver to monoethyglycinexylidide following by hydrolysis of this metabolite to 
xylidide. MEGX has approximately 80% of the activity of lignocaine for 
protecting against cardiac dysrhythmia in an animal model. This metabolite has a 
prolonged elimination half time accounting for efficacy of lignocaine infusion  in 
controlling cardiac dysrhythmia. 75% of xylidide is excreted in the urine . 
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Fig 12:- Metabolism of lignocaine  
 
Hepatic disease or decreases in hepatic blood flow which may occur during 
anaesthesia can decrease the rate of metabolism of lignocaine. Maternal clearance 
of lignocaine is prolonged in the presence of pregnancy induced hypertension and 
repeated administration of lignocaine can result in higher plasma concentrations 
than in normotensive pregnancy.  
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Plasma concentration of lignocaine 
(micrograms/mL) 
Effect 
1 – 5  Analgesia  
5-10  Circumoral numbness 
 Tinnitus 
 Skeletal muscle wasting 
 Systemic hypotension 
 Myocardial depression 
10-15 Seizures 
 Unconsciousness 
15-25 Apnea 
 Coma 
>25 Cardiovascular depression 
 
Table 4:- Lignocaine toxicity 
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Clinical use  Concentration ( 
%) 
Duration ( 
min ) 
Maximum single dose 
(mg) 
Topical  4 30-60 300 
Infiltration  0.5-1 60-240 300 or 500 with 
epinephrine  
IVRA 0.25-0.5 30-60 300 
Peripheral nerve 
block 
1-1.5 60-180 300 or 500 with 
epinephrine  
Epidural  1.5-2 60-120 300 or 500 with 
epinephrine  
Spinal  1.5-5 30-60 100 
 
Table 5:- Clinical usage of lignocaine  
Lignocaine administered intravenously also decreases anaesthetic 
requirements for volatile drugs(35). Lignocaine also may be administered 
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intravenously in the perioperative period as a cough suppressant . In this regard, 
the cough reflex during intubation of the trachea is suppressed by plasma 
concentrations of lignocaine > 2 micrograms /mL (36) . 
Intravenous lignocaine has been postulated to decrease the post operative 
stress and improve anaesthetic depth. Lignocaine also possesses significant 
antibacterial effects(33). Inhaled lignocaine attenuates histamine induced 
bronchospasm and induces airway anaesthesia reflecting topical airway 
anaesthesia.  
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CHAPTER 9 
INTRACUFF ALKALINIZED LIGNOCAINE  
Alkalinized lidocaine in the endotracheal tube (ETT) cuff decreases the 
incidence of cough and throat pain on emergence after surgery lasting more than 2 
hours. However, alkalinized lidocaine needs 60–120 minutes to cross the ETT cuff 
membrane; therefore, its usefulness in shorter duration surgery is unknown.  
During general anesthesia using nitrous oxide  the cuff pressure increases as 
the temperature of the cuff rises and nitrous oxide diffuses into it more rapidly . 
This overinflation of the ETT cuff has been associated with damage to pharyngeal 
mucosa and recurrent laryngeal nerve palsy. These complications can be prevented 
by filling the ETT cuffs with lignocaine.  
Alkalinization of lignocaine shortens the onset of a neural blockade, 
enhances the depth of blockade and increases the spread of the blockade. The pH 
of commercial preparation of local anesthetics range from 3.9 to 6.5. 
Alkalinization increases the percentage of local anaesthetic existing in the lipid 
soluble form that is available to diffuse lipid cellular barriers.  
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Lidocaine when used as endotracheal tube (ETT) cuff inflation media 
reduces the postintubation related sore throat and cough. A  lower incidence of  
endotracheal tube  discomfort and sore throat after 24 hours and lower systolic 
arterial pressure at the time of extubation has also been observed when lignocaine 
is used as the cuff inflation media (36). Tracheostomized patients, who have to keep 
the tube for a long time and whose discomfort seems to come mainly from the 
inflated cuff, can benefit from intracuff  lidocaine(37). Pressures in  cuffs filled  with 
lignocaine were significantly lower than in  cuffs filled air. 
For patients with high peak inflation pressure, an injection of a large volume 
of lignocaine into the cuff is needed because the minimum occlusive pressure 
increases linearly with peak inflation pressure (38). It should be ascertained, not to 
use more than the maximum allowable dose. 
In addition, intracuff lidocaine does not increase the cuff volume during the 
maintenance of general anesthesia with nitrous oxide. It would be more effective 
for certain kinds of surgery like neuro or craniofacial surgery because this type of 
surgery usually takes long time, and the pilot balloon port cannot be accessible for 
the cuff pressure adjustment without interrupting the surgical procedure. 
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CHAPTER 10 
REVIEW OF LITERATURE 
1. Huang et al(39) reported that alkalization of lidocaine can promote the in 
vitro diffusion across the endotracheal tube cuff many tens of times. The 
alkalization of lidocaine and the surgery of long duration would make the method 
more effective. Use of a heated breathing circuit may have some additive effect 
because warming of lidocaine solution can increase the diffusion across the cuff 
membrane.   
2. Loeser et al(40) in their found that the use of uncuffed tubes resulted in a 
significantly higher incidence of sore throat than the use of cuffed tubes, even 
when the patients breathed warmed and humidified gases. It was thought that this 
could be due to nonhumidified air being drawn across the airway mucosa during 
spontaneous respiration. There was a higher incidence of sore throat when all the 
cuffed tubes were lubricated with lignocaine ointments, as opposed to a 
water‐soluble jelly or no lubricant at all. However, the incidence was as high as 
90% when the uncuffed tubes were lubricated with 4% lignocaine jelly, and the 
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severity of sore throat in these patients was significantly greater. Conversely, a 
comparison between intubation with dry tubes or a tube lubricated with jelly 
containing 1% cinchocaine led the investigators to suggest that the use of 
lubricants containing a local anaesthetic may be beneficial. Of the 248 patients in 
that study, 39% who were intubated with a dry tube complained of sore throat on 
the first postoperative day compared with 24% who were intubated with a 
lubricated tube, a significant difference. After the first postoperative day, the 
incidence decreased rapidly in both groups. A further comparison was made in 60 
patients between lubrication of the tube with jelly containing cinchocaine and 
lubrication with the same jelly without cinchocaine(40). The incidence of sore throat 
was 38% in the non cinchocaine group vs 25% in the cinchocaine group, which 
was not statistically significant, although it might have become so with greater 
numbers of patients.  Subgroup analysis revealed that both alkalinized lidocaine 
and non-alkalinized lidocaine  offered protection compared with control groups. 
Regarding the pain intensity of post operative sore throat at 1 h, the mean in 
intervention group was 14.1 mm on Visual Analogue scale while the control was 
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29.1 mm; the mean difference between lidocaine and the control was significant 
both in the alkalinized and non-alkalinized subgroups. 
 
3. Prerana P Shroff et al (41) conducted a  prospective randomized, controlled study 
over 3 months and examined the efficacy of different media used for inflation of 
tracheal tube cuffs. The patients were divided into three equal groups (air, isotonic 
saline and alkalinized lignocaine as inflation media) using sealed envelope 
technique. The volume of the inflation medium, intracuff pressure, duration of 
intubation, volume of the inflation medium withdrawn from the cuff and 
complications like tube intolerance, coughing on tube, restlessness, hoarseness, 
sorethroat, breathlessness and laryngospasm were analysed. After intubation at all 
intervals, the intracuff pressure was higher in the air group with statistical 
significance at 5 min, 30 min, 1 h and just before extubation when air and saline 
groups were comparable and at all intervals after intubation up to just before 
extubation when air and lignocaine groups were comparable. The volume of air 
increased just before extubation in the air group, as compared with a fall in volume 
in the other groups. Tube intolerance, hoarseness and sore throat were least in the 
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lignocaine group. Hence, they concluded that alkalinized 2% lignocaine and saline 
are better cuff inflation media, than air. 
 
4. PapuNath et al (42) conducted a prospective double-blind randomized controlled 
trial to test the hypothesis that alkalinized lidocaine would reduce the incidence of 
emergence cough after surgeries lasting <120 minutes. American Society of 
Anesthesiologists PS  I–III patients were  randomized into 1 of 2 groups receiving 
either alkalinized lidocaine (group AL) or saline (group S) to inflate the ETT cuff. 
Cuffs were prefilled >90 minutes before intubation with either 2 mL of 2% 
lidocaine and 8 mL of 8.4% bicarbonate (group AL) or 10 mL of normal saline 
(group S). Cuffs were emptied immediately before intubation. After intubation, 
either 2 mL of 2% lidocaine (AL) or 2 mL of saline (S) were injected into the cuff. 
Additional 8.4% bicarbonate (AL) or saline (S) was injected into the cuff until 
therewas no air leak. Anesthesia was maintained using desflurane, rocuronium, and 
either fentanyl or sufentanil to maintain vital signs within 20% of baseline values. 
Opioids administered in prophylaxis of extubation cough were proscribed.  The 
incidence of extubation cough in group AL was 12%, significantly lower (1-sided 
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P = .045) than the 22% incidence in group S. The 1-tailed risk ratio for cough in 
group AL was 0.55 (0–0.94, P = .045). the conclusion derived was that alkalinized 
lidocaine in the ETT cuff significantly decreased general anesthesia emergence 
cough after surgeries with an average duration of slightly <1 hour. 
 
5. P.do Nascimento et al (43) studied laryngotracheal morbidity in children after 
tracheal intubation using tracheal tube cuffs filled with alkalinised lidocaine. They 
used 20 cmH2O for the cuff pressures  and the pressure transmitted to the tracheal 
mucosa against the capillaries was based on Pascal's principle. The formula 
‘p=ρgh’ was applied. They concluded that there was decreased incidence of cough 
following extubation when alkalinized lignocaine was used to inflate the cuff.  
 
6. In a study conducted by Ahmed et al (44) a total of 64 patients who expected to 
require ventilatory support for a period of more than 48 h were randomly assigned 
to groups S and L. In group S, the endotracheal tube (ETT) cuffs were inflated with 
normal saline. In group L, the ETT cuffs were inflated with lidocaine 2% and 
sodium bicarbonate 8.4%. The investigator and the surgical intensive care unit staff 
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were blinded to the nature of cuff-filled solutions. Sedation was maintained with 
propofol and fentanyl infusions. The total requirements for propofol and fentanyl, 
frequency and severity of cough and number of ineffective triggering during the 
first 24 h of mechanical ventilation were recorded. 
There was a significant reduction (about 30%) in the requirements for 
propofol and fentanyl in patients who received intracuff alkalinized lidocaine; P < 
0.001. The frequency and severity of cough were significantly lower in group L 
compared with group S and the frequency of ineffective triggering was 
significantly lower in group L; P < 0.001 for both comparisons. They concluded 
that Intracuff alkalized lidocaine increases ETT tolerance and hence, decreases 
sedatives/analgesics requirements for mechanically ventilated patients. This results 
in improved patient-ventilator synchronization. 
 
7. Shroff PP, Patil V. (45)  examined the efficacy of different media used for 
inflation of tracheal tube cuffs. In their  prospective randomized, controlled study 
over 3 months, there were 150 patients of either sex undergoing surgery under 
general anaesthesia with controlled ventilation with nitrous oxide and oxygen. The 
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patients were divided into three equal groups (air, isotonic saline and alkalinized 
lignocaine as inflation media) using sealed envelope technique. The volume of the 
inflation medium, intracuff pressure, duration of intubation, volume of the inflation 
medium withdrawn from the cuff and complications like tube intolerance, 
coughing on tube, restlessness, hoarseness, sore throat, breathlessness and 
laryngospasm were analysed.  The intracuff pressure was higher in the air group 
with statistical significance at 5 min, 30 min, 1 h and just before extubation when 
air and saline groups were comparable and at all intervals after intubation up to just 
before extubation when air and lignocaine groups were comparable. The volume of 
air increased just before extubation in the air group, as compared with a fall in 
volume in the other groups. Tube intolerance, hoarseness and sore throat were least 
in the lignocaine group. They found that alkalinized 2% lignocaine and saline are 
better cuff inflation media, than air. 
8. In a study conducted by Yoshihiro Momota et al (46)  lidocaine 
hydrochloride and alkalinized lidocaine hydrochloride solutions were filled in 
endotracheal tube cuffs to determine the rate of diffusion of lidocaine across 
the cuffs, and assess the usefulness of these cuffs as a drug delivery system. 
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Oral RAE® tracheal tubes were filled with three different lidocaine solutions, 
i.e., mixtures of 4% lidocaine hydrochloride solution and distilled water, 4% 
lidocaine hydrochloride solution and 8.4% sodium bicarbonate solution 
(LSB-Gr), and 4% lidocaine hydrochloride solution and dipotassium 
phosphate solution (LDP-Gr). Cuffs filled with the relevant lidocaine solution 
were placed in beakers filled with distilled water. A 100 μL sample of the 
water in the vessel was taken from each beaker every 30 minutes for 360 
minutes to determine the concentration of lidocaine diffused across the cuff 
using fluorescence polarization immunoassay. The cuff surface was observed 
after 60, 180, and 360 minutes of exposure for changes in the structure of the 
material. The results indicate that alkalinization of intracuff lidocaine 
increases the rate of diffusion of lidocaine across the endotracheal tube cuff.  
 
9. In a randomized controlled trial by Souissi et al(47),   they concluded that Intracuff 
160 mg alkalinized lidocaine reduces cough upon emergence from N2O-free 
general anesthesia.  This study evaluated  the benefits of endotracheal tube (ETT) 
intracuff alkalinized lidocaine during N2O-free general anesthesia by assessing the 
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in vitro effect of alkalinization on lidocaine diffusion kinetics across the cuff's 
membrane and evaluating, in a randomized controlled clinical trial, the impact of 
160 mg of intracuff alkalinized lidocaine on cough upon emergence from 
anesthesia for surgery lasting > 120 min. In the clinical trial, 80 adult patients 
(American Society of Anesthesiologists physical status I-III) undergoing urological 
or gynecological surgery expected to last > 120 min and scheduled for N2O-free 
general anesthesia were enrolled. Their  in vitro study confirmed that alkalinization 
increases lidocaine diffusion across the membrane of ETT cuffs and suggested that 
the lidocaine diffusion rate is associated with the initial intracuff lidocaine 
quantity. Their clinical trial demonstrated that, compared with the saline group, 
160 mg of intracuff alkalinized lidocaine reduced the incidence of cough upon 
emergence from N2O-free general anesthesia (76% vs 34%, respectively; 
difference 42%; 95% confidence interval, 21% to 62%; P < 0.001) while having no 
clinical impact on secondary outcomes. 
 
10. Vandse R et al(48)   in a Randomized Double Blind Control study compared  the 
efficacy of intracuff alkalinized lidocaine to low dose Remifentanil infusion in 
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attenuating the endotracheal tube induced emergence Phenomena.120 ASA I-III 
patients, aged 18-65 years, were randomly assigned to receive intracuff alkalinized 
lidocaine (2% lidocaine mixed 1:1 with 1.4% NaHCO3) or an intravenous 
remifentanil infusion (0.05-0.5 mcg/ kg/min) combined with intracuff saline during 
desflurane-based general anesthesia. At the end of surgery, after desflurane was 
turned off in the assigned group, low dose remifentanil, or its equivalent placebo 
was decreased to one-tenth of the mean dose but not less than 0.01 mcg/kg/min and 
it was continued until extubation. A blinded researcher observed each patient from 
the time desflurane was discontinued until at least five minutes after 
extubation. Coughing was evaluated as either present or not, and graded on a point 
scale based on severity. The patients were also observed for development of any 
adverse events along with the vital signs during this emergence phase.  
The incidence (44% vs 67%, p=0.02) and severity of coughing, overall, was 
significantly less in the lidocaine group compared to remifentanil group. The 
lidocaine group also had a lower incidence of significant coughing  (25% vs 49%, 
p=0.009). The mean arterial pressure (MAP) in the lidocaine group was lower than 
the remifentanil group at extubation and 5 minutes after extubation. It was 
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concluded thatIntracuff alkalinized lidocaine (ICL) is more effective in reducing 
the incidence and severity of coughing compared to a low dose remifentanil 
infusion during emergence from desflurane based anesthesia.  
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CHAPTER 11 
 
MATERIALS AND METHODS 
This study was done in patients undergoing elective surgical procedures 
lasting for more than two hours under general anesthesia in the Department of 
Otorhinolaryngology and  Department of General Surgery, Stanley Medical 
college, Chennai. This was a randomized, prospective comparative study 
conducted on 150 patients over a period of six months. Patients were explained 
about the procedure in detail and informed written consent was obtained. The 
approval of the Institutional Ethical Committee was obtained.   
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SAMPLE SIZE AND RANDOMIZATION  
The sample size of 75 was arrived with the formula given below: 
 
To find the significant difference between the bivariate samples in Paired 
groups the Paired sample t-test was used & for Independent groups the Unpaired 
sample t-test was used.  
To find the association of significance in categorical data the Chi-Square test 
was used.  
In all the above statistical tools the probability value 0.05 will be considered 
as significant level.  
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STUDY DESIGN 
Prospective , randomized , comparative, single blinded  study was 
conducted.  
PRE ANAESTHETIC EVALUATION 
Patients aged between 18-60 years scheduled to undergo elective surgical 
procedures lasting for more than 120 min under general anaesthesia were subjected 
to pre anaesthetic evaluation in our study.  
Routine blood investigations were evaluated which included hemoglobin, 
hematocrit, blood urea, serum creatinine. Detailed history about past medical 
diseases like Diabetes mellitus, hypertension, Asthma, Tuberculosis, Seizure 
disorder, previous intake of medications and vices like smoking, tobacco chewing, 
alcohol consumption were elicited. History about previous surgery performed 
under general anesthesia was also elicited.  
Airway assessment was made based on Modified Mallampati classification, 
range of neck movements and upper lip bite test.  
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Examination of cardiovascular, respiratory and neurological system was 
carried out in all patients included in the study . 
Patients were assessed under the American Soceity of Anaesthsiologists – 
Physical Status classification.  
Patients not fulfilling the inclusion criteria were excluded from the study.  
INCLUSION CRITERIA 
All patients assessed under ASA physical status classification I and II aged 18- 
60 yrs scheduled to undergo surgery under general anaesthesia lasting for more 
than 2 hours.   
EXCLUSION CRITERIA 
1.  Patients with difficult airway i.e. Modified Mallampatti grade III/IV, 
2. Patients with history suggestive of Gastro esophageal reflux,  
3. Patients with history of laryngeal or tracheal surgery and history of asthma,  
cardiovascular disease, smoking.  
4. Recent respiratory infection, 
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5. Requirement of more than one attempt for endotracheal intubation   
6. Patients who need nasogastric tube intraoperatively  
7. Surgery lasting less than 40 min   
8. No consent for study.   
MATERIALS 
The equipments, drugs, and monitors required for endotracheal intubation were 
kept ready for the conduct of anaesthesia : 
EQUIPMENTS : 
1. Oxygen source  
2. Suction apparatus  
3. Cuff pressure manometer  
4. End tidal carbon dioxide analyzer 
MONITORS: 
Continuous ECG, Pulse oximetery, Non invasive blood pressure, End tidal carbon 
dioxide analyzer.  
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METHODOLOGY 
Subjects were  allocated into two groups, Group(A) where the endotracheal 
tube cuff  filled with alkalinized lignocaine 6.5 ml (130 mg) made alkalinized with 
1.4% sodium bicarbonate 1.5 ml (the sodium bicarbonate 7.5% is available) and 
Group (B) were the endotracheal tube cuff is  filled with intracuff air according to 
computer generated randomization sheet.  
Standard monitors were attached which include ECG, NIBP, SPO2; ETCO2. 
Study subjects were  premedicated with InjGlycopyrrolate 0.005mg/kg body 
weight, Inj Midazolam 1mg, Inj Fentanyl 2 microgram/kg body weight. Baseline 
hemodynamic parameters being  noted. Patients were preoxygenated with 100% 
oxygen for 3 min. and induced with Inj. Thiopentone  5mg/kg body weight, Inj. 
Atracurium 0.5mg/kg . 
Female and male patients were intubated with ET tube size of 7mm  and 
8.5mm respectively.  The endotracheal tube was inflated to  cuff pressure set at 20 
cm of water .  For group (B) the amount of air required to attain the set cuff 
pressure that is 20 cm of water measured and the same amount of alkalinized 
 71 
lignocaine injected to inflate the cuff. Cuff pressure was recorded using a cuff 
pressure manometer at the start and end of surgery . 
Anaesthesia  maintained with Nitrous: Oxygen (35:65), InjAtracurium top 
up was  administered, 1/4th the intubating dose, depending upon the EtCO2 
changes. Lungs were mechanically ventilated with tidal volume of 8-10ml/kg body 
weight. Pulse oximeter, Non invasive blood pressure, ECG and EtCO2 monitored  
At the end of surgery, Patient  reversed with InjGlycopyrrolate 0.005 mg/kg 
body weight and Inj Neostigmine 0.05 mg/kg body weight. Cuff pressure was 
measured just before deflating the cuff and recorded.  Extubation  performed after 
checking for adequate spontaneous ventilation, ability to follow verbal commands 
(eye opening, tongue protrusion) , presence of protective airway reflexes and return 
of adequate muscle power.  
 Patients  were assessed for sore throat, at 0 minutes, 1 hour, 6 hours, 12 hrs& 
24 hours after extubation.  Sore throat was recorded and graded according to the 
post operative scoring system. Other features like post extubation cough, nausea, 
vomiting, hoarseness of voice and evidence of aspiration were recorded as either 
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occurred or not occurred by another anaesthesiologist who was not present at the 
time of intubation.  We recorded any adverse events intraoperatively and post 
operatively.  
 
Table 6:- Post operative sore throat grading (49) 
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CHAPTER 12 
OBSERVATIONS AND RESULTS  
FINDINGS:  
A prospective observational study on the effect of intracuff alkalinized 
lignocaine on the incidence of post operative sore throat and cough after general 
anaesthesia in a tertiary care center revealed the following findings. All patients 
assessed under ASA physical status classification I and II aged 18- 60 yrs 
scheduled to undergo surgery lasting for more than 2 hours were included in the 
study.  
 
Age distribution 
The following figures 1 and 2 shows the age distribution of the patients in 
the air group and lignocaine group respectively. The mean age group (in years) in 
air group is 32.96 (S.D=10.44) and in lignocaine group is 40.08 (S.D=13.928).  
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Figure 13:- Age distribution in air group    Figure 14:- Age distribution in   
        lignocaine group 
 
Gender distribution among the samples 
 
The following figure and table shows the gender distribution among the samples. 
Females were more in number in each of the groups 
(Air=54.7%;Lignocaine=50.7%).  
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Figure 15:- Gender distribution of the sample 
 
 cuff Total 
air Lignocaine 
SEX Female 41 (54.7%) 38 (50.7%) 79 
Male 34 (45.3%) 37 (49.3%) 71 
Total 75 75 150 
Table 7:- Gender distribution among the samples 
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Distribution of sample according to planned surgical procedure : 
The following figure shows distribution of patients in both the groups with respect 
to the surgical procedure . 
 
Fig 16:- Distribution of sample with respect to surgical procedure while using air 
as cuff inflation medium.   
    
Fig 17:- Distribution  of sample with respect to surgical procedure while using 
alkalinized lignocaine as cuff inflation medium.   
ASA Physical status among the two groups 
43 
32 
Intracuff air group 
otorhinolaryngological
abdominal
47 
28 
Intracuff alkalinized lignocaine  
otorhinolaryngological
abdominal
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The following figures and tables show that there is no significant difference in 
terms of ASA physical status between both the groups. 
 
Figure 18: ASA Physical Status 
Table 8:- Distribution of sample in terms of ASA physical status  
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A S A  P S I  A S A  P S I I  
Air Lignocaine
 cuff Total  
air lignocaine  
ASA Physical status ASA PSI 66 56 122  
ASA PSII 9 19 28  
Total 75 75 150  
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Cuff pressure at the end of the surgery 
The following figures show the cuff pressure at the start and at the end of the 
surgery. The cuff pressure at the end of surgery showed a one and a half to two 
fold increase compared to initial cuff pressure in the air group. However, the final 
cuff pressure in the lignocaine group was similar to their initial cuff pressures. The 
two groups differ significantly with a  p value <0.05 
 
Fig 19:- Cuff pressure at the end of surgery  
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Table 9:- Cuff pressure at the end of the surgery 
 
Post operative sore throat immediately after extubation : 
The following tables and figures show the severity of sore throat immediately after 
extubation .  Score 0 - no sore throat , Score 1 - minimal - patient answered in the 
 Cuff Total   
air Lignocaine Chi 
square 
value  
p value  
cuff pressure 
(end) 
20 0 39 39   
25 0 31 31   
30 1 4 5   
35 29 0 29 142.891 <0.05 
40 43 1 44   
45 2 0 2   
Total 75 75 150   
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affirmative when asked about sore throat , Score 2 - moderate - patient complained 
of sore throat on his/her own   
 
Figure 20:- Post operative Sore throat after extubation 
 
Table 10:- Severity of sore throat after extubation 
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 cuff Total   
air lignocaine Chi square 
value 
p value 
0 
MIN 
0 0 39 39   
1 56 35 91 60.046 <0.05 
2 19 1 20   
Total 75 75 150   
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Immediately after extubation, the severity of post operative sore throat was  more ( 
score 1 ) in the air group compared to lignocaine group.  
 
Sore throat at 1 hour after extubation : 
The lignocaine group showed lesser severity of post operative sore throat 
compared to air group one hour after extubation.  
 
Figure 21:- Sore throat at 1 hour after extubation 
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 cuff Total   
Air lignocaine Chi 
square 
value  
 p value 
1 HR 0 30 69 69   
1 45 6 81 127.778 <0.05 
Total 75 75 150   
Table 11 : Sore throat at  1 hour after extubation 
 
Sore throat 6 hours after extubation : 
The subjects belonging to both groups did not vary sugnificantly in terms of 
severity of post operative sore throat 6 hours after extubation.  
 
 83 
 
Figure 22:- Sore throat at 6 hours after extubation 
 
 cuff Total   
air lignocaine Chi 
square 
value  
 p value 
6HRS 0 67 75 142 8.451 >0.05 
1 8 0 8   
Total 75 75 150   
Table 12: Sore throat at 6 hours after extubation 
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Other features 
The following table and figures show comparison of  incidence of the other 
features like post extubation cough, nausea, vomiting and hoarseness of voice 
among the two groups. Nausea and vomiting was present in 91 patients (air=45; 
lignocaine=46). Statistical analysis shows that  p>0.005 which is statistically 
insignificant.  
 
Fig 23:- Incidence of other features associated with extubation between air and 
lignocaine group  
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Table 13:- Other features associated with extubation 
 
Differences between Male and  female subjects among two groups with 
respect to sore throat just after extubation : ( 0 Min) 
There was significant difference among males and females only in the air 
group with a p value <0.05. The following figures and tables show the differences 
 cuff Total  
air lignocaine    p value  
OTHER 
FEATURES 
cough 22 13 35  
cough nausea 
vomiting 
17 5 22  
Nausea and 
vomiting 
45 46 91 >0.05 
nil 0 2 2  
Total 75 75 150  
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in the severity of post operative sore throat among males and females just after 
extubation.  
 
 
 
Figure 24:- Difference between male and female in intracuff Air group 
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Figure 25:-  Difference between male and female in intracuff alkalinized 
Lignocaine group 
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Table 14: Difference in postoperative sorethroat severity between male and female 
in air group at 0 mins  
Lignocaine SEX Total 
F M 
0 MIN 0 17 22 39 
1 21 14 35 
2 0 1 1 
Total 38 37 75 
Table 15: Difference in postoperative severity between male and female in 
intracuff alkalinized Lignocaine group at 0 mins
Air SEX Total 
F M 
0 MIN 1 26 30 56 
2 15 4 19 
Total 41 34 75 
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CHAPTER 13 
DISCUSSION 
In our study comparing the effect alkalinized lignocaine and air as inflation 
media of the cuff  it was found that using alkalinized lignocaine as the cuff 
inflation medium led to a signiﬁcant reduction in the incidence of sore throat  upon 
emergence from  general anesthesia. Also,  the incidence of other side effects 
associated with endotracheal intubation  like postoperative cough , hoarseness of 
voice, PONV  were also decreased in comparison to the group in which air was 
used as the cuff inflation media.  
The distribution of the sample according to gender, age, ASA physical status and 
type of surgical procedure were comparable among both the groups. 
In our clinical study, the cuff pressure was recorded at the start and end of the 
surgery in both groups. The initial cuff pressure was maintained at 20 cm H2O in 
both the groups and the change in the cuff pressure towards the end of surgery 
were compared in both the groups. The Chi square test showed that the difference 
between the initial and final cuff pressure in the lignocaine group was statistically 
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significant with p value <0.05 compared to the air group. The final cuff pressure in 
air filled cuffs showed higher values ranging from 29- 45 cm H2O implying 
diffusion of nitrous oxide throughout the duration of surgery.  
However, the cuff pressure in the lignocaine group towards the end of surgery did 
not show a drastic increase from their initial pressures. An approximate increase of 
25% in the final cuff pressure was noted.  
The comparison of sore throat at various intervals after extubation among the the 
two groups were computed statistically using the Chi Square test. Immediately 
after extubation, the severity of post operative sore throat was more ( score 1) in 
the air group compared to the lignocaine group , which proved to statistically 
significant ( Chi square value - 60.046 , p value <0.05).  
One  hour after extubation, the severity of post operative sore throat was 
significantly less in the lignocaine group as compared to the air group. At 6 hours, 
12 hours and 24 hours after extubation, subjects belonging to both the groups did 
not vary significantly in terms of severity of post operative sore throat.  
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Other features associated with emergence phenomenon like nausea, vomiting, 
cough and hoarseness of voice were also compared between the two groups. The 
incidence of cough was higher in the air group thus suggesting cough suppressant 
effect of lignocaine. This is in accordance with the study conducted by Fegan et 
al(49) which showed decreased incidence of cough 4 - 8 minutes after extubation.  
However, the incidence of nausea, vomiting, and bucking was similar among both 
the groups. This is in contrast to the study conducted y Dr. Wasim Salman et al(50) 
which showed decreased incidence of nausea, vomiting, bucking and restlesness 
after extubation with intracuff lignocaine.  
Our results showed that the male patients reported a higher incidence of post 
operative sore throat in the air as compared to their female counterparts which is 
most likely due to insertion of larger sized endotracheal tube. However, the 
severity of post operative throat in the lignocaine group immediately after 
extubation was more among female patients.  
Earlier studies evaluating the efﬁcacy of intracuff lidocaine regarding similar 
clinical outcomes (i.e., postoperative sore throat and coughing) used larger 
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quantities of non-alkalinized lidocaine (200-500 mg) in an attempt to increase its 
diffusion —possibly increasing the risk of toxicity in the event of cuff rupture. We 
now know that alkalinization reduces the required amount of intracuff lidocaine 
needed while maintaining its effectiveness. 
In a study conducted by Souisii H et al(47), 160 mg of alkalinized lignocaine was 
used to inflate the cuff and it was found that significant amount of lignocaine 
diffused via the cuff in two hours. In a study by Shroff et al.(45), 40 mg of intracuff 
alkalinized lidocaine had no impact on cough at emergence compared with 
intracuffsaline.In contrast, using a larger amount of alkalinized lidocaine (200 mg), 
Huang et al(39). observed a signiﬁcant decrease in cough compared to saline. Even 
though it was tested in a population of smokers, similar effects of alkalinized 
lidocaine (138 ± 52 mg) vs saline were subsequently found by another group.   
 Considering its diffusion dynamics and clinical safety proﬁle, we used 130 mg of 
alkalinized lidocaine as the cuff-ﬁlling medium in this clinical study. Nitrous oxide 
usage during anesthetic management of patients is associated with cuff over-
inﬂation, which in turn is associated with damage to the pharyngeal mucosa.  
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The use of intracuff liquids is known to prevent overinﬂation by limiting the 
diffusion of N2O inside the cuff. In these speciﬁc anesthetic conditions, prevention 
of over-inﬂation by any cuff-ﬁlling liquids (e.g., saline or alkalinized lidocaine vs 
air in the cuff) may therefore be a more likely mechanism to explain the reduced 
incidence of sore throat, in contrast to the potential local anesthetic effect of 
lidocaine. Hence, monitoring of endotracheal tube cuff pressure during general 
anaesthesia is of paramount importance . 
In fact, lidocaine diffusion from an ETT cuff inﬂated farther away from the vocal 
cord may produce a cough suppressant effect .In our clinical trial, only patients 
whose surgery was estimated to last 120 min or more were enrolled. Our rationale 
was that this period would provide sufﬁcient diffusion time to obtain an effective 
local concentration of anesthetic to block the rapidly adapting stretch receptors, 
located within the tracheal mucosa, that are responsible for the cough reﬂex. 
Animal studies suggest that a lidocaine concentration of 155 mg/mL  is necessary 
to block these receptors.  Other potentially confounding factors (including 
narcotics, non-steroidal anti-inﬂammatory drugs, time under anesthesia) were 
similar in the two treatment groups. We found no evidence of aspiration either of 
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the groups. Our results could be generalized to other surgery of the same average 
duration for adult patients of both sexes.  
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CHAPTER 14 
CONCLUSION  
In our study we conclude that inflating the cuff of the endotracheal tube with 
alkalinized lidocaine avoids the cuff overinflation due to rapid trans-cuff N2O 
diffusion during general anesthesia with nitrous-oxygen mixture. Hence, inflating 
the endotracheal tube cuff with alkalinized lignocaine is an alternative method to 
prevent post operative sore throat and other potential complications of extubation 
including post operative cough and hoarseness of voice which results from cuff 
overinflation in patients undergoing general anaesthesia. 
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ANNEXURE  
QUESTIONAIRE 
 
PATIENT DETAILS: 
 
Name:     Age:   Sex:   
 
IP No. : 
CLINICAL DIAGNOSIS: 
 
SURGERY PLANNED : 
 
PRE OPERATIVE ASSESSMENT  : 
AIRWAY :   DENTITION : NECK :  SPINE : 
Pulse :    BP :    RR :   Temp : 
CVS  :      RS : 
P/A :      CNS: 
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INVESTIGATIONS : 
Hb%          TC                                            Platelets: 
RBS:              Urea:           Creatinine:            Na+ :K+: 
CXR : 
ECG : 
 
HISTORY OF RECENT RESPIRATORY TRACT INFECTION : 
HISTORY OF PREVIOUS SURGERY DONE UNDER GENERAL ANAESTHESIA: 
 
HISTORY OF DRUG INTAKE : 
 
PATIENT ASSESSED UNDER ASA PS – 
 
GRADING OF POST OPERATIVE SORE THROAT  
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FEATURE                                 SCORE  
 
  DURATION AFTER 
EXTUBATION  
0 min  1 hour  6hrs  12hrs  24 hours 
No sore throat at any time since 
the surgery (0) 
     
Minimal – patient answered in 
the affirmative when asked 
about sore throat (1) 
     
Moderate – patient complained 
of sore throat on his/her own (2) 
     
Severe- patient is in obvious 
distress (3) 
     
 
FEATURE  PRESENT / ABSENT  
Post operative cough  
Nausea and vomiting   
Hoarseness of voice   
Evidence of Aspiration   
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INFORMATION SHEET 
TITLE :“EFFECT OF INTRACUFF ALKALINIZED LIGNOCAINE ON THE 
INCIDENCE OF POST OPERATIVE SORE THROAT AND COUGH” 
Name of Investigator :  Dr. NASREEN KAJA ,  Name of Participant : 
Purpose of Research :To prevent post operative sore throat and cough after general 
anaesthesia.  
Study Design  :Prospective Study. 
Study Procedures :Patient will be subjected to general anesthesia with the cuff of the 
endotracheal tube being inflated with alkalinized lignocaine.  
Possible Risks :No risks to the patient 
Possible benefits 
To patient : A better understanding of their problem so as to devise a plan of management 
which suits their needs. 
To doctor & to other people :Based upon the study, post operative sore throat and cough 
after general anaesthesia can be reduced.  
Confidentiality of the information obtained from you :The privacy of the patients in the 
research will be maintained throughout the study. In the event of any publication or 
presentation resulting from the research, no personally identifiable information will be 
shared. 
Can you decide to stop participating in the study :Taking part in this study is voluntary. 
You are free to decide whether to participate in this study or to withdraw at any time 
How will your decision to not participate in the study affect you :Your decision will not 
result in any loss of benefits to which you are otherwise entitled. 
 
 
Signature of Investigator          Signature of  Participant 
Date : 
Place : 
PATIENT CONSENT FORM 
 
 
 
 
 
 
 
 
Patient may check (☑) these boxes 
I confirm that I have understood the purpose of procedure for the above study. I have the opportunity 
to ask question and all my questions and doubts have been answered to my complete satisfaction. ❏ 
I understand that my participation in the study is voluntary and that I am free to withdraw at any time 
without giving reason, without my legal rights being affected. ❏ 
I understand that sponsor of the clinical study, others working on the sponsor’s behalf, the Ethics 
committee and the regulatory authorities will not need my permission to look at my health 
records, both in respect of current study and any further research that may be conducted in 
relation to it, even if I withdraw from the study I agree to this access. However, I understand that 
my identity will not be revealed in any information released to third parties or published, unless 
as required under the law. I agree not to restrict the use of any data or results that arise from this 
study. ❏ 
I agree to take part in the above study and to comply with the instructions given during the study and 
faithfully cooperate with the study team and to immediately inform the study staff if I suffer from 
any deterioration in my health or well being or any unexpected or unusual symptoms. ❏ 
I hereby consent to participate in this study 
 
❏ 
I hereby give permission to undergo complete clinical examination and diagnostic tests including 
hematological, biochemical, radiological tests and to undergo treatment ❏ 
 
Signature/thumb impression 
Patient’s Name and Address:
Signature of Investigator 
Study Investigator’s Name: 
Dr.NASREEN KAJA  
Study Detail : “EFFECT OF INTRACUFF ALKALINIZED 
LIGNOCAINE ON THE INCIDENCE OF POST 
OPERATIVE SORE THROAT AND COUGH” 
Study Centre : Govt. Stanley medical college , Chennai. 
Patient’s Name :  
Patient’s Age :  
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INFORMED CONSENT 
A STUDY ON THE EFFECT OF INTRACUFF ALKALINIZED LIGNOCAINE ON THE 
INCIDENCE OF POST OPERATIVE SORE THROAT AND COUGH  
AT GOVERNMENT STANLEY HOSPITAL, CHENNAI. 
 
நான்இந்தஆராய்ச்சியில்விவரங்களைமுற்றிலும்புாிந்துககாண்டேன். 
ஆய்வில்பங்குஎடுத்துடபாது, 
சாத்தியமானஅபாயங்கள்மற்றும்பயன்களைபற்றிநான்அறிந்துள்டைன். 
நான்எந்தகவாருடவளையிலும்ஆய்வில்இருந்துதிரும்பமுடியும், அதன்பின்னர், 
நான்வழக்கம்டபால்மருத்துவசிகிச்ளசகபறமுடியும்என்றுபுாிந்துககாள்கிடறன் 
நான்ஆய்வில்பங்குஎடுத்துபணம்எளதயும்கபறமுடியாதுஎன்றுஅறிந்துள்டைன். 
இந்தஆய்வின்முடிவுகள்எந்தகமடிக்கல்ஜர்னலில்கவைியிேப்பேஇருந்தால்நான்எதிர்க்
கவில்ளை, என்தனிப்பட்ேஅளேயாைத்ளதகவைிப்படுத்தப்பட்டுஇருக்ககூோது. 
நான்இந்தஆய்வில்பங்ககடுப்பதன்மூைம்நான்என்னகசய்யடபாகிடறன்என்றுகதாியும் 
நான்இந்தஆய்வில்என்முழுஒத்துளழப்ளபயும்ககாடுப்டபன்என்றுஉறுதியைிக்கிடறன். 
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NAME AGE/SEX IP. NO. DIAGNOSIS PROCEDURE DONE cuf pressure (end) 0 MIN 1 HR 6HRS 12HRS 24HRS OTHER FEATURES cuff
ASA Physical 
status
priyanka 19/f 300343 CSOM tympanoplasty 25 1 0 0 0 0 nausea and vomiting lignocaine ASA PSI
prakasam 56/m 188762 CSOM cortical mastoidectomy 20 0 0 0 0 0 cough lignocaine ASA PSI
desamuthu 50/f 1936895 DNS FESS 25 1 0 0 0 0 nausea and vomiting lignocaine ASA PSI
baskar 42/m 1314078 sinonasal polyposis FESS 20 2 1 0 0 0 cough , nausea vomiting lignocaine ASA PSI
dilli babu 19/m 1914023 DNS FESS 20 0 0 0 0 0 cough lignocaine ASA PSI
jegankumar 38/m 1924304 DNS FESS 25 0 0 0 0 0 nausea and vomiting lignocaine ASA PSI
vijaykumar 19/m 1884555 CSOM tympanoplasty 20 1 1 0 0 0 nausea and vomiting lignocaine ASA PSI
livingston 18/m 1927016 CSOM cortical mastoidectomy 25 1 0 0 0 0 Nausea and vomiting and cough lignocaine ASA PSI
venkatesh 24/m 1913344 DNS FESS 20 0 0 0 0 0 Nausea and vomiting and cough lignocaine ASA PSI
ajith 22/m 1919529 DNS FESS 20 1 0 0 0 0 nausea and vomiting lignocaine ASA PSI
umapathy 40/m 1923031 chronic sinusitis FESS 20 1 1 0 0 0 cough nausea vomiting lignocaine ASA PSII
komaladevi 24/f 1916879 DNS FESS 20 0 0 0 0 0 cough nausea vomiting lignocaine ASA PSII
nagavalli 29/f 309055 DNS FESS 25 1 0 0 0 0 nausea and vomiting lignocaine ASA PSII
saradha 38/f 1934255 chronic sinusitis FESS 20 1 0 0 0 0 cough lignocaine ASA PSII
pandiyan rajan 38/m 1948565 DNS FESS 25 1 1 0 0 0 nausea and vomiting lignocaine ASA PSII
shalini 20/f 1838163 DNS FESS 20 0 0 0 0 0 nausea and vomiting lignocaine ASA PSII
divyashree 23/f 1875737 DNS FESS 20 1 0 0 0 0 nausea and vomiting lignocaine ASA PSII
sagila 32f 1910408 CSOM cortical mastoidectomy 20 0 0 0 0 0 nausea and vomiting lignocaine ASA PSII
azhagavel 38m 861852 DNS FESS 30 1 0 0 0 0 nausea and vomiting lignocaine ASA PSII
shobiya 19f 857137 DNS FESS 20 0 1 0 0 0 nil lignocaine ASA PSII
shantipriya 24f 1964535 DNS FESS 25 1 0 0 0 0 nausea and vomiting lignocaine ASA PSII
ibrahim 27m 1847959 DNS FESS 20 0 0 0 0 0 nausea and vomiting lignocaine ASA PSII
kanniyammal 54f 1967708 sinonasal polyposis fess 25 1 0 0 0 0 nausea and vomiting lignocaine ASA PSII
muhukumar 39m 1845023 DNS FESS 20 1 0 0 0 0 nausea and vomiting lignocaine ASA PSII
rajendran 42m 1847959 DNS FESS 25 0 0 0 0 0 nausea and vomiting lignocaine ASA PSII
radhika 29f 1954635 DNS FESS 20 1 0 0 0 0 nil lignocaine ASA PSII
selvi 32f 1963955 CSOM cortical mastoidectomy 20 1 0 0 0 0 nausea and vomiting lignocaine ASA PSII
kali 56m 1807404 inguinal hernia lap hernia 20 1 0 0 0 0 nausea and vomiting lignocaine ASA PSII
sumathy 31f 1808839 cholelithiasis lap cholecystectomy 30 0 0 0 0 0 nausea and vomiting lignocaine ASA PS I 
selvi 40f 1802278 cholelithiasis lap cholecystectomy 20 0 0 0 0 0 nausea and vomiting lignocaine ASA PS I 
banumathy 63f 1890108 cholelithiasis lap cholecystectomy 25 0 0 0 0 0 nausea and vomiting lignocaine ASA PS I 
sridhar 53m 1772710 pleomorphic adenoma superficial parotidectomy 20 1 0 0 0 0 nausea and vomiting lignocaine ASA PS I 
viswanathan 68m 1804178 cholelithiasis lap cholecystectomy 20 0 0 0 0 0 cough lignocaine ASA PS I 
janaki 28f 1805467 gb polyp lap cholecystectomy 20 1 0 0 0 0 cough lignocaine ASA PS I 
ponniyan selvi 62f 1801639 ca breast mrm 20 1 1 0 0 0 cough lignocaine ASA PS I 
indumathy 37f 1807211 ca breast lumpectomy 20 0 0 0 0 0 cough lignocaine ASA PS I 
kulandaram 52f 1806222 ca breast mrm 20 1 0 0 0 0 nausea and vomiting lignocaine ASA PS I 
senthil 40m 1821300 inguinal hernia lap hernia 25 0 0 0 0 0 nausea and vomiting lignocaine ASA PS I I
devaki 60f 1818841 ovarian cyst d lap 20 1 0 0 0 0 nausea and vomiting lignocaine ASA PS I 
murugaperumal 44m 1810594 incisional hernia mesh repair 25 0 0 0 0 0 nausea and vomiting lignocaine ASA PS I 
mohanraj 60m 1819146 cholelithiasis lap cholecystectomy 20 0 0 0 0 0 nausea and vomiting lignocaine ASA PS I 
salima 35f 1819382 cholelithiasis lap cholecystectomy 25 1 0 0 0 0 nausea and vomiting lignocaine ASA PS I 
selvi 38f 1809037 adnexal mass d lap 20 0 0 0 0 0 nausea and vomiting lignocaine ASA PS I 
indumathy 45f 1811437 ca breast mrm 25 1 0 0 0 0 nausea and vomiting lignocaine ASA PS I 
indumathy 30f 1812500 cholelithiasis lap cholecystectomy 25 0 0 0 0 0 nausea and vomiting lignocaine ASA PS I 
amsa 59f 1812528 cholelithiasis lap cholecystectomy 25 0 0 0 0 0 nausea and vomiting lignocaine ASA PS I 
rubavathy 32f 1810000 cholelithiasis lap cholecystectomy 25 0 0 0 0 0 nausea and vomiting lignocaine ASA PS I 
shankar 43m 1812773 cholelithiasis lap cholecystectomy 25 0 0 0 0 0 cough lignocaine ASA PS I 
gandimathy 61f 1807770 cholelithiasis lap cholecystectomy 25 1 0 0 0 0 cough lignocaine ASA PS I 
ramanujam 50m 1823977 inguinal hernia lap hernia 30 0 0 0 0 0 cough lignocaine ASA PS I 
abdul rafi 71m 1820890 inguinal hernia lap hernia 20 0 0 0 0 0 cough lignocaine ASA PS I 
sangara reddy 61m 1822654 cholelithiasis lap cholecystectomy 20 0 0 0 0 0 cough lignocaine ASA PS I 
sumathy 43f 1827586 incisional hernia mesh repair 25 1 0 0 0 0 cough lignocaine ASA PS I 
maheshwari 60f 1802692 cholelithiasis lap cholecystectomy 20 0 0 0 0 0 cough lignocaine ASA PS I 
noorjahan 48f 1825692 cholelithiasis lap cholecystectomy 20 0 0 0 0 0 cough lignocaine ASA PS I 
naveenkumar 27m 1826136 gynaecomastia websters procedure 25 1 0 0 0 0 cough lignocaine ASA PS I 
josna 42f 1826139 parotid sialadenitis superficial parotidectomy 25 0 0 0 0 0 cough lignocaine ASA PS I 
rameela 28f 1804311 cholelithiasis lap cholecystectomy 20 0 0 0 0 0 nausea and vomiting lignocaine ASA PS I 
sarain kumar 25m 1832108 inguinal hernia lap hernia 25 0 0 0 0 0 nausea and vomiting lignocaine ASA PS I 
murugan 54m 1830563 inguinal hernia lap hernia 20 1 0 0 0 0 nausea and vomiting lignocaine ASA PS I 
kamalnathan 45m 1882097 cholelithiasis lap cholecystectomy 25 0 0 0 0 0 nausea and vomiting lignocaine ASA PS I 
arifa 16f 1833776 abdominal pain for evaluation d lap 20 1 0 0 0 0 nausea and vomiting lignocaine ASA PS I 
elangovan 30m 1832070 cholelithiasis lap cholecystectomy 25 0 0 0 0 0 nausea and vomiting lignocaine ASA PS I 
vajravel 57m 1830591 incisional hernia mesh repair 20 0 0 0 0 0 nausea and vomiting lignocaine ASA PS I 
hajira 48f 1840591 CSOM cortical mastoidectomy 30 1 0 0 0 0 nausea and vomiting lignocaine ASA PS I 
dhanasekhar 62m 1855963 inguinal hernia lap hernia 25 0 0 0 0 0 nausea and vomiting lignocaine ASA PS I 
ramamoorthy 49m 1857938 inguinal hernia lap hernia 25 0 0 0 0 0 nausea and vomiting lignocaine ASA PS I 
ezhilarasan 30m 1860736 gynaecomastia websters procedure 25 0 0 0 0 0 cough lignocaine ASA PS I 
selvaraj 42m 1855305 cholelithiasis lap cholecystectomy 20 1 0 0 0 0 cough lignocaine ASA PS I 
govindaraj 38m 1856417 incisional hernia mesh repair 25 0 0 0 0 0 cough lignocaine ASA PS I 
rajeshwari 26f 1805427 DNS FESS 20 1 0 0 0 0 cough lignocaine ASA PS I 
suresh kumar 34m 1693393 DNS FESS 25 1 0 0 0 0 cough lignocaine ASA PS I 
sasikala 42f 1808829 chronic sinusitis FESS 20 1 0 0 0 0 nausea and vomiting lignocaine ASA PS I 
vijaya 49f 1808293 sinonasal polyposis FESS 25 0 0 0 0 0 nausea and vomiting lignocaine ASA PS I 
shathikali 37m 1807837 CSOM cortical mastoidectomy 40 1 0 0 0 0 nausea and vomiting lignocaine ASA PS I 
Anbarasan 46m 1772748 recurrent submandibular sialadesubmanidibular gland excision 35 2 1 0 0 0 cough air ASA PS I 
Mary 60f 1174261 csom cortical mastoidectomy 35 2 1 0 0 0 Nausea and vomiting air ASA PS I 
Devi 36f 1731845 csom cortcal mastoidectomy 40 1 1 0 0 0 Nausea and vomiting air ASA PS I 
Keerthika 20f 1735319 DNS Septal correction 40 1 1 0 0 0 Nausea and vomiting air ASA PS I 
Decnan 42m 1686101 B/L oto scelerosis L stapedectomy 35 1 1 0 0 0 Nausea and vomiting air ASA PS I 
Lalitha 30f 1706813 DNS FESS 40 2 1 0 0 0 Nausea and vomiting air ASA PS I 
Kumaresan 38m 1724676 sinonasal polyposis FESS 35 1 1 0 0 0 Nausea and vomiting air ASA PS I 
Kailasam 29m 1810765 facial nerve palsy facial decompression 40 1 1 0 0 0 Nausea and vomiting air ASA PS I 
Jeyanthi 48f 181043 csom cortical mastoidectomy 45 2 1 0 0 0 Nausea and vomiting and cough air ASA PS I 
Vasanthi 24f 839536 csom tympanoplasty 40 2 1 0 0 0 Nausea and vomiting air ASA PS I 
Pushpa 18f 1706108 chronic sinusitis FESS 40 2 1 0 0 0 Nausea and vomiting air ASA PS I 
Saranya 25f 1725901 DNS FESS 35 1 1 0 0 0 Nausea and vomiting and cough air ASA PS I 
Regina 16f 1610391 DNS FESS 40 1 1 0 0 0 Nausea and vomiting air ASA PS I 
surya 19m 51693 DNS FESS 40 1 1 1 0 0 Nausea and vomiting air ASA PS I 
sophiya 22f 842692 csom tympanoplasty 40 1 1 0 0 0 Nausea and vomiting air ASA PS I 
babu 25m 1516837 csom cortical mastoidectomy 40 1 1 0 0 0 Nausea and vomiting air ASA PS I I
arun 19m 1809444 chronic sinusitis FESS 40 1 1 1 0 0 Nausea and vomiting and cough air ASA PS I I
abdul mubarak 28m 1709882 DNS FESS 40 2 1 0 0 0 Nausea and vomiting air ASA PS I 
joseph 32m 162813 DNS FESS 35 1 1 0 0 0 Nausea and vomiting air ASA PS I 
mohan 18m 180877 csom cortical mastoidectomy 40 1 1 0 0 0 Nausea and vomiting air ASA PS I 
selvi 36f 1640342 otosclerosis tympanoplasty 35 2 1 0 0 0 Nausea and vomiting air ASA PS I 
Anbarasan 29m 164321 csom cortical mastoidectomy 40 1 1 0 0 0 Nausea and vomiting air ASA PS I 
abdl rahim 19m 841229 DNS FESS 45 1 1 0 0 0 Nausea and vomiting and cough air ASA PS I 
hemalatha 44f 1816091 csom cortical mastoidectomy 30 1 1 0 0 0 Nausea and vomiting and cough air ASA PS I 
arif basha 17m 1703984 DNS FESS 40 2 1 0 0 0 Nausea and vomiting air ASA PS I I
shafi 37m 1716475 otosclerosis tympanoplasty 35 1 1 0 0 0 Nausea and vomiting and cough air ASA PS I 
mariyammal 38f 1676817 DNS FESS 40 1 1 0 0 0 Nausea and vomiting air ASA PS I 
krishnaveni 28f 1645069 DNS FESS 35 1 1 0 0 0 Nausea and vomiting and cough air ASA PS I 
lathapriya 22f 1710010 csom cortical mastoidectomy 40 2 1 0 0 0 Nausea and vomiting and cough air ASA PS I 
lavanya 35f 1808046 csom tympanoplasty 35 1 1 0 0 0 cough air ASA PS I 
vasanthi 34f 1773285 DNS FESS 40 1 1 0 0 0 Nausea and vomiting air ASA PS I 
yasmin banu 28f 1640148 DNS FESS 35 1 1 0 0 0 Nausea and vomiting and cough air ASA PS I 
mohana 19f 839769 DNS FESS 40 1 1 0 0 0 cough air ASA PS I 
mary 43f 8281125 csom cortical mastoidectomy 35 2 1 0 0 0 cough air ASA PS I 
revathy 32f 1633102 ac polyp FESS 40 1 1 0 0 0 cough air ASA PS I 
anbarasu 46m 1772748 submandibular calculi submanidibular gland excision 40 1 1 0 0 0 cough air ASA PS I I
balu 46m 810397 csom cortical mastoidectomy 40 1 1 0 0 0 Nausea and vomiting and cough air ASA PS I 
alamelu 30f 1634658 csom cortical mastoidectomy 40 2 1 0 0 0 cough air ASA PS I 
nandhakumar 24m 1629798 DNS FESS 35 1 1 0 0 0 cough air ASA PS I 
eswari 50f 1648212 csom cortical mastoidectomy 40 1 1 0 0 0 Nausea and vomiting and cough air ASA PS I 
sivakumar 22m 166488 csom cortical mastoidectomy 35 1 1 1 0 0 Nausea and vomiting air ASA PS I I
mahalakshmi 24f 1809266 DNS feSS 40 2 1 0 0 0 Nausea and vomiting and cough air ASA PS I 
pechimuthu 36m 1809389 DNS FESS 35 1 1 0 0 0 cough air ASA PS I 
kiruba 40m 1726450 DNS FESS 40 1 1 0 0 0 Nausea and vomiting and cough air ASA PS I 
logesh 26m 1809446 DNS feSS 40 1 1 0 0 0 Nausea and vomiting and cough air ASA PS I 
nirmala 44f 1709219 DNS FESS 40 2 1 0 0 0 Nausea and vomiting and cough air ASA PS I 
sudha 27m 811803 csom tympanoplasty 40 1 1 1 0 0 Nausea and vomiting air ASA PS I 
komathy 32f 1685446 csom cortical mastoidectomy 40 1 1 0 0 0 Nausea and vomiting air ASA PS I 
ramu 48m 1648212 csom cortical mastoidectomy 40 1 1 0 0 0 Nausea and vomiting air ASA PS I 
fathima 44f 1805857 csom cortical mastoidectomy 40 1 1 0 0 0 cough air ASA PS I 
subashini 29f 1615210 dns FESS 35 2 1 0 0 0 Nausea and vomiting air ASA PS I 
kairunnisa 28f 1843219 DNS FESS 35 1 1 1 0 0 Nausea and vomiting air ASA PS I 
abdul sardar 50 m 1807223 csom cortical mastoidectomy 35 1 1 0 0 0 Nausea and vomiting air ASA PS I I
hidayathulla 48m 176653 csom tympanoplasty 35 1 1 0 0 0 Nausea and vomiting air ASA PS I 
manjula 50f 1803719 polyp FESS 40 1 1 0 0 0 cough air ASA PS I 
vasanthy 33f 1635868 chronic sinusitis FESS 35 2 1 0 0 0 Nausea and vomiting air ASA PS I 
mahariba 36f 1362721 csom cortical mastoidectomy 40 1 1 0 0 0 Nausea and vomiting air ASA PS I 
velu 45m 1803178 sinonasal polyposis FESS 35 1 1 1 0 0 Nausea and vomiting air ASA PS I 
logeshwari 33f 1863180 csom cortical mastoidectomy 40 1 1 0 0 0 Nausea and vomiting air ASA PS II
govindammal 38f 1803177 csom cortical mastoidectomy 40 1 1 0 0 0 Nausea and vomiting air ASA PS I 
ramu 34m 180160 facial nerve palsy facial nerve decompression 35 1 1 0 0 0 Nausea and vomiting air ASA PS I 
desarani 20f 1651565 csom cortical mastoidectomy 40 2 1 0 0 0 Nausea and vomiting air ASA PS I 
kadar basha 33m 1648463 dns FESS 35 1 1 0 0 0 cough air ASA PS I 
sethuraman 18m 1640658 DNS feSS 40 1 1 1 0 0 Nausea and vomiting air ASA PS I 
mary 43f 800484 otosclerosis stapedotomy 35 1 1 0 0 0 nausea and vomiting air ASA PS I 
selvi 37f 1678708 csom cortical mastoidectomy 40 1 1 1 0 0 nausea and vomiting air ASA PS II
saravanan 23m 1662982 csom cortical mastoidectomy 35 1 1 0 0 0 Nausea and vomiting air ASA PS I 
balkis 40f 830416 csom myringoplasty 40 1 1 0 0 0 Nausea and vomiting air ASA PS I 
indhumathy 46f 1638526 ac polyp FESS 35 2 1 0 0 0 Nausea and vomiting and cough air ASA PS I 
kalaiarasi 25f 1849306 renal pelvic calculus pcnl 40 1 1 0 0 0 cough air ASA PS I 
ravi 40m 1851672 puj calculus pcnl 35 1 1 0 0 0 Nausea and vomiting air ASA PS I 
gunasekaran 50m 1853200 renal pelvic calculus pcnl 40 2 1 0 0 0 Nausea and vomiting air ASA PS I 
manikam 28m 1854517 staghorn calculus pcnl 35 1 1 0 0 0 Nausea and vomiting and cough air ASA PS I 
ajay 18m 1907802 DNS FESS 35 1 1 0 0 0 Nausea and vomiting air ASA PS I I
ameena 32f 1876639 csom myringoplasty 40 1 1 0 0 0 Nausea and vomiting air ASA PS I 
sandhiya 17f 1655341 CSOM cortical mastoidectomy 35 1 1 0 0 0 Nausea and vomiting air ASA PS I 
